We are live on ! Find out more
FLNA

Filana Therapeutics

163 hedge funds and large institutions have $390M invested in Filana Therapeutics in 2022 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 50 increasing their positions, 52 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

4% less repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 52

2.57% less ownership

Funds ownership: 28.82%26.25% (-2.6%)

5% less funds holding

Funds holding: 171163 (-8)

22% less capital invested

Capital invested by funds: $503M → $390M (-$113M)

25% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 28

39% less call options, than puts

Call options by funds: $107M | Put options by funds: $175M

Holders
163
Holders Change
-8
Holders Change %
-4.68%
% of All Funds
2.57%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
21
Increased
50
Reduced
52
Closed
28
Calls
$107M
Puts
$175M
Net Calls
-$67.9M
Net Calls Change
-$27.2M
Name Holding Trade Value Shares
Change
Change in
Stake
Neuberger Berman Group
26
Neuberger Berman Group
New York
$1.6M +$212K +5,000 +13%
RhumbLine Advisers
27
RhumbLine Advisers
Massachusetts
$1.53M +$94.5K +2,230 +6%
Goldman Sachs
28
Goldman Sachs
New York
$1.46M -$666K -15,717 -29%
AllianceBernstein
29
AllianceBernstein
Tennessee
$1.39M +$4.24K +100 +0.3%
LPL Financial
30
LPL Financial
California
$1.38M -$71.3K -1,682 -4%
CS
31
Credit Suisse
Switzerland
$1.36M +$152K +3,589 +11%
Legal & General Group
32
Legal & General Group
United Kingdom
$1.31M +$52.5K +1,239 +4%
IFO
33
Intrepid Family Office
Florida
$1.3M +$67.8K +1,600 +5%
AC
34
Aristides Capital
Kentucky
$1.29M +$212K +5,000 +17%
UBS AM
35
UBS AM
Illinois
$1.19M +$243K +5,727 +22%
KPWS
36
Kestra Private Wealth Services
Texas
$1.17M +$1.33M +31,500 New
GC
37
Guggenheim Capital
Illinois
$1.15M -$168K -3,974 -11%
Bank of America
38
Bank of America
North Carolina
$1.1M -$10.4M -245,462 -89%
JP Morgan Chase
39
JP Morgan Chase
New York
$1.07M +$175K +4,123 +17%
T. Rowe Price Associates
40
T. Rowe Price Associates
Maryland
$1.05M +$226K +5,344 +23%
New York State Common Retirement Fund
41
New York State Common Retirement Fund
New York
$1.03M -$1.65K -39 -0.1%
CAN
42
Cetera Advisor Networks
California
$927K +$119K +2,817 +13%
Barclays
43
Barclays
United Kingdom
$901K -$3.68M -86,747 -78%
Deutsche Bank
44
Deutsche Bank
Germany
$895K -$90K -2,124 -8%
MIM
45
MetLife Investment Management
New Jersey
$810K +$341K +8,050 +58%
AIG
46
American International Group
New York
$706K -$56.6K -1,337 -7%
PPW
47
Pinnacle Private Wealth
Massachusetts
$617K
Invesco
48
Invesco
Georgia
$602K -$14.5K -342 -2%
Cambridge Investment Research Advisors
49
Cambridge Investment Research Advisors
Iowa
$590K -$6.1K -144 -0.9%
CCFM
50
Clear Creek Financial Management
Washington
$588K +$214K +5,050 +47%

FLNA Hedge Fund Activity: Q1 2022 in Review

163 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Filana Therapeutics (FLNA) for Q1 2022, worth a combined $390M — down 22% from $503M a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of FLNA and 21 opened new positions — a net loss of 7 holders — while 52 trimmed existing stakes and 50 added.

The largest buyer was Group One Trading, adding an estimated $6.02M. The largest seller was Morgan Stanley, cutting an estimated $17.2M.

  • 163 institutional investors held Filana Therapeutics (FLNA) as of Q1 2022, down from 171 in Q4 2021.
  • Funds reported $390M of Filana Therapeutics stock for Q1 2022, down 22% quarter-over-quarter.
  • 21 funds opened new Filana Therapeutics positions in Q1 2022 and 28 closed out, a net change of -7 holders.
  • The largest Filana Therapeutics buyer in Q1 2022 was Group One Trading, an estimated $6.02M added.
  • The largest Filana Therapeutics seller in Q1 2022 was Morgan Stanley, an estimated $17.2M sold.

Based on aggregated 13F filings for Q1 2022.